Jing Jie Yu, MD

Professor Emeritus

Organization:

West Virginia University School of Medicine

Department:

Biochemistry and Molecular Medicine

Classification:

Unknown

1. Salkini MW, Yang XQ, Hashmi FH, Kandzari SJ, Hogan T, Morley C, Zekan D, Werner Z, Williams DJ, Guo Y, Matthew TL, Spangler M and Yu JJ. First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules – A Case Report. Anticancer Research 42:1339-1344, 2022. doi:10.21873/anticanres.15602

2. Yu JJ, Hogan T, Morley C, Crigger C, Jiao S, Williams DJ, Salkini MW, Yang XQ, Liang XB, Cecil C, Winn AC, Zheng J, Guo Y, Petros W, Jiang BH and Washington IM. "Adverse Effects Profile of Dicycloplatin (DCP) Offers Chemotherapeutic Advance Over Cisplatin and Carboplatin." ANTICANCER RESEARCH 39: 4455-4462 (2019) doi:10.21873/anticanres.13618

3. Salkini MW, Morley C, Crigger C, Jiao S, Yu JJ. "West Virginia Resident is First American to Receive Dicycloplatin Chemotherapy: A WVU Urologic Oncology Case Report." Clinical Oncology & Research ISSN 2613-4942 doi:10.31487/j.COR.2018.02.005 (2018).

4. Yu JJ, Jiao S, Salkini MW, Morley C, Williams DJ, Liang XB, Yan BX, Winn AC, Guo Y, Zheng J, Hogan T, Gyure K, Petros W. "Seventeen-Month Report For First American Cancer Patient To Receive Dicycloplatin Chemotherapy." Adv Inv Pha The Medic 1: 10-13 (2018).

5. Yang XQ, Yu JJ (corresponding author), Guo Y and Mueller MD. "Dicycloplatin, a Platinum - Based Supramolecule with 4 Hydrogen Bonds, is a Promising Chemotherapy Drug in eBook", Bentham Science Publishers, Atta-ur-Rahman (Ed.). Title: Frontiers in Clinical Drug Research - Anti-Cancer Agents, Vol. 4, Chapter 7, 339-362 (2017).

6. Yu JJ, Salkini MW, Jiao S, Hogan T, Guo Y, Liang X, Yang B, Zhang L, Gyure K. "The first American cancer patient to receive dicycloplatin chemotherapy: A case report."  J Cancer Res Ther. Vol. 5 (9):56–60; doi:10.14312/2052-4994.2017-11 (2017).

7. Yu JJ. "DNA damage repair and TP53 gene in platinum-drug resistance." Int J Clin Pharmacol Pharmacother 2016, 1: 121. https://doi.org/10.15344/2016/2456-3501/121 (2016).

8. Yu JJ. "NER pathway and wild-type p53 in platinum-drug resistance and inhibition of chemoresistance with PCK3145, a PSP94 peptide derivative." In: Understand Cancer - Research and Treatment. ISBN: 978-1-922227-386. iConcept Press Limited: Brisbane, Australia, June, 2015. Retrieved from https://www.iconceptpress.com/books/understand-cancer--research-and-treatment/11000145/ (2015).

9. He J, Yu JJ, Xu Q, Wang L, Zheng JZ, Liu LZ and Jiang BH. "Downregulation of ATG14 by EGR1-MIR152 Sensitizes Ovarian Cancer Cells to Cisplatin-induced Apoptosis by Inhibiting Cyto-protective Autophagy." Autophagy, DOI:10.1080/15548627.2015.1009781, http://dx.doi.org/10.1080/15548627.2015.1009781 (2015).

10. Yu JJ, Yang XQ, Song QH, Mueller MD and Remick SC. "Dicycloplatin, a novel platinum analog in chemotherapy: Synthesis of Chinese preclinical and clinical profile and emerging mechanistic studies" [Review Article]. Anticancer Research 34: 455-464, (2014).

11. Yan BX, Ma JX, Zhang J, Guo Y, Riedel H, Mueller MD, Remick SC and Yu JJ. "PSP94 contributes chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer." Oncogene 33, 5288–5294, (2014).

12. Ma JX, Yan BX, Zhang J, Jiang BH, Guo Y, Riedel H, Mueller MD, Remick SC and Yu JJ. "PSP94, an upstream signaling mediator of prostasin found highly elevated in ovarian cancer." Cell Death and Disease 5, e1407; doi:10.1038/cddis.2014.374, (2014).

13. Yan BX, Ma JX, Zhang J, Guo Y, Mueller MD, Remick SC and Yu JJ. "Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin." Cell Death and Disease 5, e995; doi:10.1038/cddis.2013.523, (2014).

Non-Programmatically Aligned Cancer Center Members

Cisplatin and homologs continue to play a key role in treating cancers. However, platinum-based chemotherapy often results in relatively low survival due to the development of drug resistance. Enhanced DNA repair resulting in reduced apoptosis is the major mechanism of acquired platinum resistance. To block the DNA repair pathway, thereby enhancing platinum sensitivity, making cancer chemotherapy more effective.

A promising novel anticancer drug dicycloplatin (DCP), approved by China FDA demonstrated as effective as cisplatin and carboplatin – with more tolerable side effects – is an important therapeutic advance. Clinical investigation of dicycloplatin in the United States and other countries is warranted.